American Premium Water Corp. Announces Q4 Guidence and Update on Hydrogen CBD Release

March 27, 2018 6:00 AM

Guidance on Q4 Results: Revenues Projected to Be 600%-700% Higher; LALPINA Hydrogen CBD on Track for June Release PLAYA VISTA, CA / ACCESSWIRE / March. 27, 2018 / American Premium Water Corporation (OTC PINK: HIPH) (the "Company") updates shareholders as to Q4 financial projections and release of LALPINA Hydrogen CBD. American Premium Water Corporation (OTC Pink: HIPH), after a review of its financials, wishes to inform prospective investors and...

Read more

Qrons Exercises Dartmouth Option

March 26, 2018 10:10 AM

MIAMI, FL / ACCESSWIRE / March 26, 2018 / Qrons Inc. (OTC PINK: QRON) ("Qrons" or the "Company"), a preclinical biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries ("TBIs"), announced today that it was exercising its option under its September 27, 2017 Option Agreement with Dartmouth College ("Dartmouth") to enter into good faith negotiations with Dartmouth for...

Read more

Vitro Bio-Pharma 1st Quarter 2018 Financial Results of Operations

March 23, 2018 9:30 AM

GOLDEN, CO / ACCESSWIRE / March 23, 2018 / Vitro Diagnostics, Inc. (OTC PINK: VODG), dba Vitro BioPharma, announced its 1st quarter ended January 31st, 2018 financial results of operations. Vitro Diagnostics Inc. ("Vitro") is pleased to announce a record 1st quarter in Stem Cell Revenues. Vitro recorded 1st quarter revenues of $87,185 vs $57,041 an increase of 53% over the same comparative quarter last year. In addition, Stem Cell therapies...

Read more

MorphoSys Files Registration Statement in the United States for a Proposed American Depositary Shares (ADS) Offering

March 22, 2018 3:30 PM

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / March 22, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC PINK: MPSYY) announced today that it filed a Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) for a proposed offering of ordinary shares in the form of American Depositary Shares ("ADSs") in the United States. The final number of ADSs to be offered and the price for the offering have not yet...

Read more

American Premium Water Corp.’s (OTC:HIPH) LALPINA Hydrogen Distribution in General Nutrition Center (GNC)

March 22, 2018 6:00 AM

LALPINA Hydrogen CBD also expected to be a part of same GNC pilot program PLAYA VISTA, CA / ACCESSWIRE / March 22, 2018 / American Premium Water Corporation (OTC PINK: HIPH) ("APWC") announces that its LALPINA Hydrogen has established distribution in General Nutrition Center (GNC). LALPINA Hydrogen, as part of a pilot program, is currently available for sale at two southern California locations; GNC Walnut, CA located at 20687 Amar Road and GNC...

Read more

Clinical Data Presentations at AAT in Alzheimer's Disease

March 14, 2018 3:15 AM

Clinical Data Presentations at AAT in Alzheimer's Disease Support Investigating Gantenerumab in Higher Doses in New Pivotal Phase 3 Trials - Three abstracts will be presented at the upcoming Alzheimer's and Parkinson's Disease conference AAT-AD/PDTM Focus Meeting 2018, thereof one as Late Breaking Abstract. - Gantenerumab showed greater and consistent amyloid beta reduction in the brain after one year of treatment at higher doses in open-label...

Read more

Genoptix Enters into Agreement to Market and Distribute Rosetta Genomics' Testing Services Worldwide

March 13, 2018 8:00 AM

Genoptix Will Have Exclusive Distribution Rights in the U.S. and Non-exclusive Rights in Most Geographies Outside the U.S. CARLSBAD, CA, PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / March 13, 2018 / Genoptix, Inc., a leading oncology diagnostic laboratory, and Rosetta Genomics Ltd. (NASDAQ: ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, jointly...

Read more

MorphoSys Reports Updated Data from L-MIND Study of MOR208 plus Lenalidomide in Aggressive Lymphoma (r/r DLBCL)

March 13, 2018 2:57 AM

- New data from the ongoing L-MIND trial of MOR208 plus lenalidomide in relapsed/refractory DLBCL patients ineligible for high-dose chemotherapy and autologous stem cell transplantation confirm earlier data reported from this trial - 81 patients enrolled, 68 available for efficacy assessment at cut-off date - Preliminary median progression-free survival (PFS) not reached, preliminary PFS rate at 12 months of 50.4% - Overall response rate...

Read more

Rosetta Sets a New Date for Shareholder Meeting to Approve Genoptix Merger

March 12, 2018 8:00 AM

Previously announced meeting date of April 6, 2018, for its extraordinary general meeting of shareholders, has been cancelled and rescheduled for April 17, 2018 New record date for shareholder meeting to approve the merger is March 20, 2018 and Rosetta Genomics strongly urges shareholders to vote for new transaction as its cash position is insufficient to fund operations beyond a short period of time PHILADELPHIA, PA and REHOVOT,...

Read more

Genoptix Completes Acquisition of PersonalizeDx from Rosetta Genomics

March 5, 2018 8:30 AM

-First step in the process of Genoptix acquiring all of Rosetta Genomics -Next step is the completion of a merger for $8 million in cash pursuant to which value to Rosetta Genomics' equity holders is preliminarily estimated to be $0.40 - $0.45 per ordinary share, after deductions for debt, warrant termination payments, fees, expenses and other items -Record date for shareholder meeting to approve the merger is March 9, 2018 and Rosetta Genomics...

Read more

Yield10 Bioscience to Present at the Inaugural LD Micro Virtual Conference

March 1, 2018 8:30 AM

WOBURN, MA / ACCESSWIRE / March 1, 2018 / Yield10 Bioscience, Inc. (NASDAQ: YTEN), a company focused on developing new technologies to achieve step-change improvements to crop yield to enhance global food security, announced today that Oliver Peoples, Ph.D., President and Chief Executive Officer of Yield 10, will be presenting at the LD Micro Virtual Conference on Tuesday, March 6, 2018 at 12:30 pm EST/3:30 pm PT. The conference will be held via...

Read more

Genoptix Enters into New Agreements to Acquire Rosetta Genomics for $9 Million in Cash

February 27, 2018 8:05 PM

- Value to Rosetta Genomics' Equity Holders is Preliminarily Estimated to be $0.40 - $0.45 Per Ordinary Share, After Deductions for Debt, Warrant Termination Payments, Fees, Expenses and Other Items - Rosetta Genomics Strongly Urges Shareholders to Vote for New Transaction as its Cash Position is Insufficient to Fund Operations Beyond a Short Period of Time CARLSBAD, CA, PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / February 27, 2018 /...

Read more

Rosetta Genomics Announces Results from Extraordinary General Meeting of Shareholders to Vote on Proposed Merger with Genoptix

February 23, 2018 8:30 AM

Although shares voted were more than 2-to-1 in favor of the merger, the proposal failed to secure a majority of shares outstanding Company considering alternative options with Genoptix LAKE FOREST, CA; PHILADELPHIA, PA; and REHOVOT, ISRAEL / ACCESSWIRE / February 23, 2018 / Rosetta Genomics Ltd. (NASDAQ: ROSG) ("Rosetta" or "the Company"), a genomic diagnostics company that improves treatment decisions by providing timely and...

Read more

MorphoSys Announces That Tremfya(R) (Guselkumab) Data Demonstrated Long-Term Skin Clearance In Patients With Moderate-To-Severe Plaque Psoriasis

February 20, 2018 7:05 AM

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / February 20, 2018 / MorphoSys AG (FSE: MOR) (XETRA: MOR) (OTC PINK: MPSYY) announced today that its licensee Janssen Research & Development, LLC (Janssen) reported data from the Phase 3 VOYAGE 2 study of TREMFYA(R) (guselkumab), which demonstrated long-term skin clearance in patients with moderate to severe plaque psoriasis. TREMFYA(R) is a fully human anti-IL-23 monoclonal antibody developed by Janssen...

Read more

MorphoSys and Galapagos Present Results from a Phase 1 Study with MOR106 in Atopic Dermatitis as Late-Breaking Abstract at the American Academy of Dermatology (AAD) Meeting in San Diego

February 17, 2018 8:30 AM

- In the study, MOR106 was generally well tolerated in atopic dermatitis (AD) patients - 83% of patients (5 out of 6) at the highest dose reached at least 50% improvement per the atopic dermatitis area and severity index (EASI-50) at week 4 - Pooled data across all dose cohorts showed 72% improvement of AD symptoms at week 12 compared to baseline in patients treated with MOR106 - Phase 2 development of MOR106 planned to be initiated in first...

Read more

Calmare Therapeutics Alerts All Shareholders of Inaccurate Information About the Company

February 16, 2018 1:54 PM

Calmare's Board and Management Remain in Place FAIRFIELD, CT / ACCESSWIRE / February 16, 2018 / Calmare Therapeutics Incorporated (OTC PINK: CTTC), the pain mitigation company ("Calmare" or the "Company"), alerts all shareholders about inaccurate information that has been disseminated regarding the Company. On Friday, February 9, 2018, a complaining group of stockholders filed with the U.S. Securities and Exchange Commission ("SEC") statements...

Read more

Qrons Raises Funds to Further Its Goals, Expands Advisory Board

February 12, 2018 11:20 AM

MIAMI, FL / ACCESSWIRE / February 12, 2018 / Qrons Inc. (OTC PINK: QRON) ("Qrons " or the "Company"), a preclinical biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries ("TBIs"), announced today that it sold 312,500 shares of its common stock and raised $500,000 in a private placement offering pursuant to an exemption from registration under Regulation S of the...

Read more

Molecular Partners Reports Significant Progress of Pipeline and Preliminary Unaudited Key Financials for 2017 - Key Value Inflection Points in 2018

February 8, 2018 1:00 AM

Research & Development:- MP0250 in multiple myeloma (MM): Promising initial safety and efficacy data from the ongoing phase 2 study of MP0250- MP0250 in EGFR-mutated non-small cell lung cancer (EGFR mut NSCLC): Following FDA approval of IND for phase 1b/2 study on track to dose first patient in Q1 2018- MP0250: Phase 1 study marks a major milestone for the DARPin® Platform, demonstrating the safety, low immunogenicity and convenience of...

Read more

Pressure BioSciences, Inc., a Leader in the Sale of Pressure-Based Solutions for the Worldwide Life Sciences Market, to Host Webinar Update for Investors

January 29, 2018 11:08 AM

Company to Discuss Expected Impact on 2018 Revenue from Recent Product Enhancements, New Field Salesforce, Technology Asset Acquisition, and Newly Issued Patents SOUTH EASTON, MA / ACCESSWIRE / January 29, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company"), a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry, today announced that Mr....

Read more

American Cryostem Corporation 2017 Year End Update

January 16, 2018 6:00 AM

EATONTOWN, NJ / ACCESSWIRE / January 16, 2018 / American CryoStem Corporation (OTC PINK: CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today released Summary corporate and financial highlight information regarding the Company's Year ending September 30, 2017; Total Revenue increased to $1,865,364 in Fiscal...

Read more